Global Women’s Health Drugs Market 2019-2024 - 277 Pipeline Products in Active Development - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 21, 2019--The “Global Women’s Health Drugs Market to 2024 - Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth” report has been added to ResearchAndMarkets.com’s offering.
“Global Women’s Health Drugs Market to 2024 Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth” covers all indications within women’s health with a particular focus on five key indications: endometriosis, polycystic ovarian syndrome (PCOS), cervical intraepithelial neoplasia (CIN), menopausal disorders and infertility.
The women’s health market represents a small but growing therapy area. There are currently 277 pipeline products in active development for women’s health, making it the 16th largest therapy area by pipeline size. Key indications within the area include endometriosis, polycystic ovarian syndrome (PCOS), cervical intraepithelial neoplasia, menopausal disorders and infertility.
The global market is projected to grow at a compound annual growth rate (CAGR) of 5.16% till 2024. This relatively strong growth will be driven by a number of factors. These include the strong growth projected for human papillomavirus (HPV) vaccines, which are administered to girls and women in order to prevent development of CIN, an abnormality of the cells on the surface of the cervix, which can progress to cervical cancer in some cases.
The women’s health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause. Many of these disorders are highly prevalent among the female population.
Some 246 licensing deals have been completed within the women’s health therapy area since 2006, demonstrating a relatively high level of activity, considering the small size of the therapy area. Co-development deal activity has been much lower, with only 78 deals completed since 2006.
The strategic consolidations landscape was largely dominated by small molecule products and products acting on G-protein coupled receptors (GPCR). The majority of deals identified were relatively low value although a small number of deals exceeded $500m in value, demonstrating that women’s health products are capable of attracting high levels of investment.
Key Topics Covered:
1 Tables & Figures
3 Key Marketed Products
4 Pipeline Landscape Assessment
5 Multi-scenario Market Forecast to 2024
6 Company Analysis and Positioning
7 Strategic Consolidations
Companies MentionedAbbVie Inc Allergan Plc Bayer AG GlaxoSmithKline Merck & Co. Pfizer Therapeutics MD
For more information about this report visit https://www.researchandmarkets.com/research/lfj362/global_womens?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190121005132/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Women’s Health,Gastrointestinal Drugs,Endocrine and Metabolic Disorders Drugs
INDUSTRY KEYWORD: WOMEN HEALTH PHARMACEUTICAL CONSUMER
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 01/21/2019 05:40 AM/DISC: 01/21/2019 05:40 AM